HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability.

Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene

Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760

Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei

Dignam, J. D., Lebovitz, R. M., & Roeder, R. G. (1983) · Nucleic Acids Research · doi:10.1093/nar/11.5.1475 · Cited by 11,262

Sequence and structure-based prediction of eukaryotic protein phosphorylation sites

Blom, N., Gammeltoft, S., & Brunak, S. (1999) · Journal of Molecular Biology · doi:10.1006/jmbi.1999.3310 · Cited by 3,212

The ErbB signaling network: receptor heterodimerization in development and cancer

Olayioye, M. A., Neve, R. M., Lane, H. A., & Hynes, N. E. (2000) · The EMBO Journal · doi:10.1093/emboj/19.13.3159 · Cited by 2,489

Molecular determinants of resistance to antiandrogen therapy

Chen, C. D., Welsbie, D. S., Tran, C., Baek, S. H., Chen, R., Vessella, R., Rosenfeld, M. G., & Sawyers, C. L. (2004) · Nature Medicine · doi:10.1038/nm972 · Cited by 2,278

Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase

Kato, S., Endoh, H., Masuhiro, Y., Kitamoto, T., Uchiyama, S., Sasaki, H., Masushige, S., Gotoh, Y., Nishida, E., Kawashima, H., et al. (1995) · Science · doi:10.1126/science.270.5241.1491 · Cited by 1,964

Phosphorylation-induced binding and transcriptional efficacy of nuclear factor CREB

Yamamoto, K. K., Gonzalez, G. A., Biggs, W., & Montminy, M. (1988) · Nature · doi:10.1038/334494a0 · Cited by 1,281

A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase

Craft, N., Shostak, Y., Carey, M., & Sawyers, C. L. (1999) · Nature Medicine · doi:10.1038/6495 · Cited by 980

The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation

Holbro, T., Beerli, R. R., Maurer, F., Koziczak, M., Barbas, C. F., & Hynes, N. E. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1537685100 · Cited by 952

Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor.

Čulig, Z., Hobisch, A., Cronauer, M. V., Radmayr, C., Trapman, J., Hittmair, A., Bartsch, G., & Klocker, H. (1994) · PubMed · Cited by 938

Androgen receptor-modulatory microRNAs provide insight into therapy resistance and therapeutic targets in advanced prostate cancer

Fletcher, C. E., Sulpice, E., Combe, S., Shibakawa, A., Leach, D. A., Hamilton, M. P., Chrysostomou, S., Sharp, A., Welti, J. C., Yuan, W., et al. (2019) · Oncogene · doi:10.1038/s41388-019-0823-5 · Cited by 70

Combinatorial androgen receptor targeted therapy for prostate cancer

Singh, P., Uzgare, A. R., Litvinov, I. V., Denmeade, S. R., & Isaacs, J. T. (2006) · Endocrine Related Cancer · doi:10.1677/erc.1.00797 · Cited by 68

A transcription-independent function of FOXO1 in inhibition of androgen-independent activation of the androgen receptor in prostate cancer cells.

Liu, P., Li, S., Gan, L., Kao, T. P., & Huang, H. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-2038 · Cited by 67

Transit of hormonal and EGF receptor-dependent signals through cholesterol-rich membranes

Freeman, M. R., Cinar, B., Kim, J., Mukhopadhyay, N. K., Vizio, D. D., Adam, R. M., & Solomon, K. R. (2006) · Steroids · doi:10.1016/j.steroids.2006.11.012 · Cited by 68

ACK1 Tyrosine Kinase Interacts with Histone Demethylase KDM3A to Regulate the Mammary Tumor Oncogene HOXA1

Mahajan, K. N., Lawrence, H. R., Lawrence, N. J., & Mahajan, N. P. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.584425 · Cited by 65

Results from a Phase I Clinical Study of the Novel Ii-Key/HER-2/neu(776–790) Hybrid Peptide Vaccine in Patients with Prostate Cancer

Perez, S. A., Kallinteris, N. L., Bisias, S., Tzonis, P., Georgakopoulou, K., Varla-Leftherioti, M., Papamichail, M., Thanos, A., Hofe, E. V., & Baxevanis, C. N. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0085 · Cited by 65

Post-Transcriptional Regulation of the Androgen Receptor by Mammalian Target of Rapamycin

Cinar, B., Benedetti, A. D., & Freeman, M. R. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3411 · Cited by 65

Sorafenib decreases proliferation and induces apoptosis of prostate cancer cells by inhibition of the androgen receptor and Akt signaling pathways

Oh, S. J., Erb, H. H. H., Hobisch, A., Santer, F. R., & Čulig, Z. (2012) · Endocrine Related Cancer · doi:10.1530/erc-11-0298 · Cited by 64

EBP1, an ErbB3-binding protein, is decreased in prostate cancer and implicated in hormone resistance

Zhang, Y., Linn, D. E., Liu, Z., Melamed, J., Tavora, F. R. F., Young, C. Y. F., Burger, A. M., & Hamburger, A. W. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0526 · Cited by 63

HER2 overcomes PTEN (loss)-induced senescence to cause aggressive prostate cancer

Ahmad, I., Patel, R., Singh, L. B., Nixon, C., Seywright, M. M., Barnetson, R. J., Brunton, V. G., Muller, W. J., Edwards, J., Sansom, O. J., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1101263108 · Cited by 63

O ‐Glycosylation‐mediated signaling circuit drives metastatic castration‐resistant prostate cancer

Tzeng, S., Tsai, C., Chao, T., Chou, Y., Yang, Y., Tsai, M., Cha, T., & Hsiao, P. (2018) · The FASEB Journal · doi:10.1096/fj.201800687 · Cited by 64

Should Intermittent Androgen Deprivation Be Used in Routine Clinical Practice?

Bhandari, M. S., Crook, J. M., & Hussain, M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.2557 · Cited by 63

Dual EGFR/HER2 Inhibition Sensitizes Prostate Cancer Cells to Androgen Withdrawal by Suppressing ErbB3

Chen, L., Mooso, B. A., Jathal, M. K., Madhav, A., Johnson, S. D., Spyk, E. N. V., Mikhailova, M., Ripoll, A. Z., Xue, L., Vinall, R. L., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1548 · Cited by 61

Epidermal growth factor induces bladder cancer cell proliferation through activation of the androgen receptor

Izumi, K., Zheng, Y., LI, Y., Zaengle, J., & Miyamoto, H. (2012) · International Journal of Oncology · doi:10.3892/ijo.2012.1593 · Cited by 61

MAPK4 promotes prostate cancer by concerted activation of androgen receptor and AKT

Shen, T., Wang, W., Zhou, W., Coleman, I. M., Cai, Q., Dong, B., Ittmann, M., Creighton, C. J., Bian, Y., Meng, Y., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci135465 · Cited by 59

Prostatic intraepithelial neoplasia and adenocarcinoma in mice expressing a probasin- Neu oncogenic transgene

Li, Z., Szabolcs, M. J., Terwilliger, J. D., & Efstratiadis, A. (2006) · Carcinogenesis · doi:10.1093/carcin/bgi324 · Cited by 60

Phospho-kinase profile of triple negative breast cancer and androgen receptor signaling

Cuenca-López, M. D., Montero, J. C., Morales, J. C., Prat, A., Pandiella, A., & Ocaña, A. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-302 · Cited by 60

Choline Kinase Alpha as an Androgen Receptor Chaperone and Prostate Cancer Therapeutic Target

Asim, M., Massie, C. E., Orafidiya, F. A., Pértega‐Gomes, N., Warren, A. Y., Esmaeili, M., Selth, L. A., Zecchini, H. I., Luko, K., Qureshi, A., et al. (2015) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djv371 · Cited by 58

Ligand-Independent and Tissue-Selective Androgen Receptor Inhibition by Pyrvinium

Lim, M. A., Otto‐Duessel, M., He, M., Su, L., Nguyen, D., Chin, E., Alliston, T. N., & Jones, J. O. (2013) · ACS Chemical Biology · doi:10.1021/cb400759d · Cited by 56

Nrdp1-Mediated Regulation of ErbB3 Expression by the Androgen Receptor in Androgen-Dependent but not Castrate-Resistant Prostate Cancer Cells

Chen, L., Siddiqui, S., Bose, S., Mooso, B. A., Asuncion, A., Bedolla, R. G., Vinall, R. L., Tepper, C. G., Gandour‐Edwards, R. F., Shi, X.-B., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4440 · Cited by 56

HER2 is not a cancer subtype but rather a pan-cancer event and is highly enriched in AR-driven breast tumors

Daemen, A., & Manning, G. (2018) · Breast Cancer Research · doi:10.1186/s13058-018-0933-y · Cited by 56

Expression and function of nuclear receptor co-activator 4: evidence of a potential role independent of co-activator activity

Kollara, A., & Brown, T. J. (2012) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-012-1000-y · Cited by 53

Longitudinal analysis of androgen deprivation of prostate cancer cells identifies pathways to androgen independence

D’Antonio, J. M., Ma, C., Monzon, F. A., & Pflug, B. R. (2008) · The Prostate · doi:10.1002/pros.20677 · Cited by 53

Biomarker Identification through Multiomics Data Analysis of Prostate Cancer Prognostication Using a Deep Learning Model and Similarity Network Fusion

Wang, T., Lee, C., Lee, T.-Y., Huang, H., Hsu, J. B., & Chang, T. (2021) · Cancers · doi:10.3390/cancers13112528 · Cited by 53

The Extracellular Matrix Stiffening: A Trigger of Prostate Cancer Progression and Castration Resistance?

Luthold, C., Hallal, T., Labbé, D. P., & Bordeleau, F. (2022) · Cancers · doi:10.3390/cancers14122887 · Cited by 62

Translating Scientific Advancement into Clinical Benefit for Castration-Resistant Prostate Cancer Patients

Attard, G., & Bono, J. S. D. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0943 · Cited by 53

Over-expression of Skp2 is associated with resistance to preoperative doxorubicin-based chemotherapy in primary breast cancer

Davidovich, S., Ben‐Izhak, O., Shapira, M., Futerman, B., & Hershko, D. (2008) · Breast Cancer Research · doi:10.1186/bcr2122 · Cited by 53

The 5α-androstanedione pathway to dihydrotestosterone in castration-resistant prostate cancer

Sharifi, N. (2012) · Journal of Investigative Medicine · doi:10.2310/jim.0b013e31823874a4 · Cited by 52

Sex Hormone Receptor Repertoire in Breast Cancer

Higa, G. M., & Fell, R. G. (2013) · International Journal of Breast Cancer · doi:10.1155/2013/284036 · Cited by 52

Steroid receptors and microRNAs: Relationships revealed

Cochrane, D. R., Cittelly, D. M., & Richer, J. K. (2010) · Steroids · doi:10.1016/j.steroids.2010.11.003 · Cited by 54

MUC1‐C oncoprotein confers androgen‐independent growth of human prostate cancer cells

Rajabi, H. N., Ahmad, R., Jin, C., Joshi, M. D., Guha, M., Alam, M., Kharbanda, S. M., & Kufe, D. W. (2012) · The Prostate · doi:10.1002/pros.22519 · Cited by 51

The role of TXNDC5 in castration-resistant prostate cancer—involvement of androgen receptor signaling pathway

Wang, L., Song, G., Chang, X., Tan, W., Pan, J., Zhu, X., Liu, Z., Mao, Q., Yu, J., & Han, B. (2014) · Oncogene · doi:10.1038/onc.2014.401 · Cited by 51

MicroRNA Signature Helps Distinguish Early from Late Biochemical Failure in Prostate Cancer

Lichner, Z., Fendler, A., Saleh, C., Nasser, A., Boles, D., Al‐Haddad, S., Kupchak, P., Dharsee, M., Nuin, P. S., Evans, K., et al. (2013) · Clinical Chemistry · doi:10.1373/clinchem.2013.205450 · Cited by 51

SPRY2 loss enhances ErbB trafficking and PI3K/AKT signalling to drive human and mouse prostate carcinogenesis

Gao, M., Patel, R., Ahmad, I., Fleming, J., Edwards, J., McCracken, S. R., Sahadevan, K., Seywright, M. M., Norman, J. C., Sansom, O. J., et al. (2012) · EMBO Molecular Medicine · doi:10.1002/emmm.201100944 · Cited by 51

Androgen Receptor Expression in Prostate Cancer Cells Is Suppressed by Activation of Epidermal Growth Factor Receptor and ErbB2

Cai, C., Portnoy, D. C., Wang, H., Jiang, X., Chen, S., & Balk, S. P. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0026 · Cited by 51

Phase II Study of Enzalutamide for Patients With Androgen Receptor–Positive Salivary Gland Cancers (Alliance A091404)

Ho, A. L., Foster, N. R., Zoroufy, A. J., Campbell, J. D., Worden, F. P., Price, K. A. R., Adkins, D. R., Bowles, D. W., Kang, H., Burtness, B. A., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.00229 · Cited by 53

The testosterone paradox of advanced prostate cancer: mechanistic insights and clinical implications

Kumar, R., Sena, L. A., Denmeade, S. R., & Kachhap, S. K. (2022) · Nature Reviews Urology · doi:10.1038/s41585-022-00686-y · Cited by 52

Identification of Kinases Regulating Prostate Cancer Cell Growth Using an RNAi Phenotypic Screen

Whitworth, H., Bhadel, S., Ivey, M. L., Conaway, M. R., Spencer, A., Hernan, R. A., Holemon, H., & Gioeli, D. G. (2012) · PLoS ONE · doi:10.1371/journal.pone.0038950 · Cited by 50

HER-2/ neu Expression in Prostate Adenocarcinoma: A Systematic Review and Meta-Analysis

Neto, A. S., Tobias‐Machado, M., Wroclawski, M. L., Fonseca, F. L. A., Teixeira, G. K., Amarante, R. D. M., Wroclawski, E. R., & del Giglio, A. (2010) · The Journal of Urology · doi:10.1016/j.juro.2010.04.077 · Cited by 50

ErbB2 Signaling Increases Androgen Receptor Expression in Abiraterone-Resistant Prostate Cancer

Gao, S., Ye, H., Gerrin, S. J., Wang, H., Sharma, A. M., Chen, S., Patnaik, A., Sowalsky, A. G., Voznesensky, O. S., Han, W., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2309 · Cited by 49

Adenylyl cyclase activating polypeptide reduces phosphorylation and toxicity of the polyglutamine-expanded androgen receptor in spinobulbar muscular atrophy

Polanco, M. J., Parodi, S., Piol, D., Stack, C. M., Chivet, M., Contestabile, A., Miranda, H. C., Lievens, P., Espinoza, S., Jochum, T., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf9526 · Cited by 48

Role of steroid receptor and coregulator mutations in hormone-dependent cancers

Groner, A. C., & Brown, M. A. (2017) · Journal of Clinical Investigation · doi:10.1172/jci88885 · Cited by 49

Inhibition of the HER2-YB1-AR axis with Lapatinib synergistically enhances Enzalutamide anti-tumor efficacy in castration resistant prostate cancer

Shiota, M., Bishop, J. L., Takeuchi, A., Nip, K. M., Cordonnier, T., Beraldi, E., Kuruma, H., Gleave, M. E., & Zoubeidi, A. (2015) · Oncotarget · doi:10.18632/oncotarget.3602 · Cited by 46

HER3 is required for the maintenance of neuregulin‐dependent and ‐independent attributes of malignant progression in prostate cancer cells

Soler, M., Mancini, F., Meca‐Cortés, Ó., Sánchez‐Cid, L., Rubio, N., López‐Fernández, S., Lozano, J. J., Blanco, J., Fernández, P. L., & Thomson, T. M. (2009) · International Journal of Cancer · doi:10.1002/ijc.24651 · Cited by 45

Pharmacological Targeting of Constitutively Active Truncated Androgen Receptor by Nigericin and Suppression of Hormone-Refractory Prostate Cancer Cell Growth

Mashima, T., Okabe, S., & Seimiya, H. (2010) · Molecular Pharmacology · doi:10.1124/mol.110.064790 · Cited by 45

Elevated levels of HER‐2/neu and androgen receptor in clinically localized prostate cancer identifies metastatic potential

Ricciardelli, C., Jackson, M. W., Choong, C. S., Stahl, J., Marshall, V. R., Horsfall, D. J., & Tilley, W. D. (2008) · The Prostate · doi:10.1002/pros.20747 · Cited by 44

EGF Prevents the Neuroendocrine Differentiation of LNCaP Cells Induced By Serum Deprivation: The Modulator Role of P13K/Akt

Orozco, R. M. M., Almaraz-Pro, C., Rodríguez‐Ubreva, J., Cortés, M. A., Ropero, S., Colomer, R., López‐Ruiz, P., & Colás, B. (2007) · Neoplasia · doi:10.1593/neo.07337 · Cited by 45

Targeting HER2 in Prostate Cancer: Where to Next?

Solit, D. B., & Rosen, N. X. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.8187 · Cited by 45

Androgen receptor signaling regulates the transcriptome of prostate cancer cells by modulating global alternative splicing

Shah, K., Gagliano, T., Garland, L., O’Hanlon, T., Bortolotti, D., Gentili, V., Rizzo, R., Giamas, G., & Dean, M. C. (2020) · Oncogene · doi:10.1038/s41388-020-01429-2 · Cited by 45

Preclinical and clinical studies with the multi-kinase inhibitor CEP-701 as treatment for prostate cancer demonstrate the inadequacy of PSA response as a primary endpoint

Collins, C., Carducci, M. A., Eisenberger, M. A., Isaacs, J. T., Partin, A. W., Пили, Р., Sinibaldi, V. J., Walczak, J. S., & Denmeade, S. R. (2007) · Cancer Biology & Therapy · doi:10.4161/cbt.6.9.4541 · Cited by 43

Anti-androgen therapy in triple-negative breast cancer

Barton, V. N., Gordon, M. A., Richer, J. K., & ELIAS, A. D. (2016) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834016646735 · Cited by 42

Plexin-B1 signalling promotes androgen receptor translocation to the nucleus

Williamson, M. P., de Winter, P., & Masters, J. R. (2015) · Oncogene · doi:10.1038/onc.2015.160 · Cited by 42

Androgen Receptor as a Therapeutic Target for Androgen Independent Prostate Cancer

Sharifi, N., & Farrar, W. L. (2006) · American Journal of Therapeutics · doi:10.1097/00045391-200603000-00013 · Cited by 42

Androgen receptor molecular biology and potential targets in prostate cancer

Wilson, E. M. (2010) · Therapeutic Advances in Urology · doi:10.1177/1756287210372380 · Cited by 40

AR Inhibitors Identified by High-Throughput Microscopy Detection of Conformational Change and Subcellular Localization

Jones, J. O., An, W. F., & Diamond, M. I. (2009) · ACS Chemical Biology · doi:10.1021/cb900024z · Cited by 39

The ErbB family and androgen receptor signaling are targets of Celecoxib in prostate cancer

Brizzolara, A., Benelli, R., Venè, R., Barboro, P., Poggi, A. D., Tosetti, F., & Ferrari, N. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.04.025 · Cited by 39

Interplay between steroid signalling and microRNAs: implications for hormone-dependent cancers

Fletcher, C. E., Dart, D. A., & Bevan, C. L. (2014) · Endocrine Related Cancer · doi:10.1530/erc-14-0208 · Cited by 37

Signalling pathways in prostate carcinogenesis: potentials for molecular-targeted therapy

Ramsay, A., & Leung, H. Y. (2009) · Clinical Science · doi:10.1042/cs20080391 · Cited by 39

Caveolin-1 and Prostate Cancer Progression

Freeman, M. R., Yang, W., & Vizio, D. D. (2012) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-1222-9_7 · Cited by 37

Target gene-specific regulation of androgen receptor activity by p42/p44 mitogen-activated protein kinase.

Agoulnik, I. U., Bingman, W. E., Nakka, M., Li, W., Wang, Q., Liu, X. S., Brown, M., & Nancy L., N. L. (2008) · Molecular Endocrinology · doi:10.1210/me.2007-0481 · Cited by 36

Transgenic Mouse Model for Rapid Pharmacodynamic Evaluation of Antiandrogens

Ellwood‐Yen, K., Wongvipat, J., & Sawyers, C. L. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1397 · Cited by 36

Non-Coding RNAs in Castration-Resistant Prostate Cancer: Regulation of Androgen Receptor Signaling and Cancer Metabolism

Shih, J.-W., Wang, L., Hung, C.-L., Kung, H.-J., & Hsieh, C. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms161226138 · Cited by 37

Immunotherapy as a Precision Medicine Tool for the Treatment of Prostate Cancer

Adamaki, M., & Zoumpourlis, V. (2021) · Cancers · doi:10.3390/cancers13020173 · Cited by 37

Opposing transcriptional programs of KLF5 and AR emerge during therapy for advanced prostate cancer

Che, M., Chaturvedi, A. P., Munro, S. A., Pitzen, S. P., Ling, A. L., Zhang, W., Mentzer, J., Ku, S., Puca, L., Zhu, Y., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26612-1 · Cited by 37

Anti-oncogenic and pro-differentiation effects of clorgyline, a monoamine oxidase A inhibitor, on high grade prostate cancer cells

Zhao, H., Flamand, V., & Peehl, D. M. (2009) · BMC Medical Genomics · doi:10.1186/1755-8794-2-55 · Cited by 36

Breast Carcinoma

Bandyopadhyay, S., Bluth, M. H., & Ali‐Fehmi, R. (2018) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2018.02.006 · Cited by 35

LRIG1 is a pleiotropic androgen receptor-regulated feedback tumor suppressor in prostate cancer

Li, Q., Liu, B., Chao, H., Ji, Y., Lu, Y., Mehmood, R., Jeter, C. R., Chen, T., Moore, J. R., Li, W., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-13532-4 · Cited by 34

ACK1–AR and AR–HOXB13 signaling axes: epigenetic regulation of lethal prostate cancers

Kim, E. H., Cao, D., Mahajan, N. P., Andriole, G. L., & Mahajan, K. N. (2020) · NAR Cancer · doi:10.1093/narcan/zcaa018 · Cited by 37

TPL2/COT/MAP3K8 (TPL2) Activation Promotes Androgen Depletion-Independent (ADI) Prostate Cancer Growth

Jeong, J. H., Bhatia, A., Toth, Z., Oh, S., Inn, K., Liao, C., Roy‐Burman, P., Melamed, J., Coetzee, G. A., & Jung, J. U. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016205 · Cited by 34

ErbB-2 Induces the Cyclin D1 Gene in Prostate Epithelial Cells In vitro and In vivo

Casimiro, M. C., Rodriguez, O. C., Pootrakul, L., Aventian, M., Lushina, N., Cromelin, C., Ferzli, G. M., Johnson, K., Fricke, S. T., Diba, F., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-1898 · Cited by 34

Exploring the role of PI3K/AKT/mTOR inhibitors in hormone-related cancers: A focus on breast and prostate cancer

Wylaź, M., Kaczmarska, A., Pajor, D., Hryniewicki, M., Gil, D., & Dulińska-Litewka, J. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115676 · Cited by 37

Vasoactive intestinal peptide (VIP) induces malignant transformation of the human prostate epithelial cell line RWPE-1

Fernández‐Martínez, A. B., Bajo, A. M., Arenas, M. I., Sánchez‐Chapado, M., Prieto, J. C., & Carmena, M. J. (2010) · Cancer Letters · doi:10.1016/j.canlet.2010.07.019 · Cited by 33

Wwox Suppresses Prostate Cancer Cell Growth through Modulation of ErbB2-Mediated Androgen Receptor Signaling

Qin, H. R., Iliopoulos, D., Nakamura, T., Costinean, S., Volinia, S., Druck, T., Sun, J., Okumura, H., & Huebner, K. (2007) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-07-0211 · Cited by 33

Small-Molecule Protein Tyrosine Kinase Inhibitors for the Treatment of Metastatic Prostate Cancer

Gallick, G. E., Corn, P. G., Zurita, A. J., & Lin, S.-H. (2011) · Future Medicinal Chemistry · doi:10.4155/fmc.11.161 · Cited by 32

Pretreatment serum level of HER2/nue as a prognostic factor in metastatic prostate cancer patients about to undergo endocrine therapy

Okegawa, T., Kinjo, M., Nutahara, K., & Higashihara, E. (2006) · International Journal of Urology · doi:10.1111/j.1442-2042.2006.01533.x · Cited by 32

ErbB-2 signaling plays a critical role in regulating androgen-sensitive and castration-resistant androgen receptor-positive prostate cancer cells

Muniyan, S., Chen, S.-J., Lin, F., Wang, Z., Mehta, P. P., Batra, S. K., & Lin, M. (2015) · Cellular Signalling · doi:10.1016/j.cellsig.2015.08.002 · Cited by 32

Lemur Tyrosine Kinase 2, a novel target in prostate cancer therapy

Shah, K., & Bradbury, N. A. (2015) · Oncotarget · doi:10.18632/oncotarget.3899 · Cited by 31

Effects of EGFR tyrosine kinase inhibitor erlotinib in prostate cancer cells in vitro

Festuccia, C., Gravina, G. L., Biordi, L. A., D’Ascenzo, S., Dolo, V., Ficorella, C., Ricevuto, E., & Tombolini, V. (2009) · The Prostate · doi:10.1002/pros.20995 · Cited by 31

Tyrosine kinase inhibitors in the treatment of prostate cancer: taking the next step in clinical development

Ojemuyiwa, M. A., Madan, R. A., & Dahut, W. L. (2014) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2014.969239 · Cited by 29

ErbB-2 signaling in advanced prostate cancer progression and potential therapy

Miller, D. R., Ingersoll, M. A., & Lin, M. (2019) · Endocrine Related Cancer · doi:10.1530/erc-19-0009 · Cited by 31

Single-cell and spatial RNA sequencing identify divergent microenvironments and progression signatures in early- versus late-onset prostate cancer

Cheng, Y., Liu, B., Xin, J., Wu, X., Li, W., Shang, J., Wu, J., Zhang, Z., Xu, B., Du, M., et al. (2025) · Nature Aging · doi:10.1038/s43587-025-00842-0 · Cited by 29

Preoperative Plasma HER2 and Epidermal Growth Factor Receptor for Staging and Prognostication in Patients with Clinically Localized Prostate Cancer

Shariat, S. F., Bensalah, K., Karam, J. A., Roehrborn, C. G., Andrea Gallina, A., Lotan, Y., Slawin, K. M., & Karakiewicz, P. I. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0330 · Cited by 28

Internalization of secreted antigen–targeted antibodies by the neonatal Fc receptor for precision imaging of the androgen receptor axis

Thorek, D. L. J., Watson, P. A., Lee, S.-G., Ku, A. T., Bournazos, S., Braun, K., Kim, K., Sjöström, K., Doran, M. G., Lamminmäki, U., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf2335 · Cited by 26

Future Aspects of CDK5 in Prostate Cancer: From Pathogenesis to Therapeutic Implications

Oner, M., Lin, E., Chen, M., Hsu, F.-N., Prince, G. M. S. H., Chiu, K.-Y., Teng, C. J., Yang, T., Wang, H., Yue, C.-H., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20163881 · Cited by 28

Prostate cancer health disparities: An immuno-biological perspective

Kumar, S., Singh, R., Malik, S., Manne, U., & Mishra, M. K. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.11.011 · Cited by 28

New drugs in prostate cancer

Armstrong, A. J., & Carducci, M. A. (2006) · Current Opinion in Urology · doi:10.1097/01.mou.0000193390.69845.bb · Cited by 27

EGF promotes neuroendocrine-like differentiation of prostate cancer cells in the presence of LY294002 through increased ErbB2 expression independent of the phosphatidylinositol 3-kinase-AKT pathway

Cortés, M. A., Cariaga-Martínez, A. E., Lobo, M. V. T., Orozco, R. M. M., Motiño, O., Rodríguez‐Ubreva, J., Angulo, J. C., López‐Ruiz, P., & Colás, B. (2012) · Carcinogenesis · doi:10.1093/carcin/bgs139 · Cited by 26

Gene interference strategies as a new tool for the treatment of prostate cancer

Boccellino, M., Alaia, C., Misso, G., Cossu, A. M., Facchini, G., Piscitelli, R., Quagliuolo, L., & Caraglia, M. (2015) · Endocrine · doi:10.1007/s12020-015-0629-3 · Cited by 25

Potentiation of antitumour activity of docetaxel by combination with trastuzumab in a human prostate cancer xenograft model and underlying mechanisms

Legrier, M.-E., Oudard, S. M., Judde, J.-G., Guyader, C., Pinieux, G. D. B. D., Boyé, K., de Crémoux, P., Dutrillaux, B., & Poupon, M. F. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603553 · Cited by 25

HER2/HER3 heterodimers in prostate cancer

Freeman, M. R. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.10.018 · Cited by 25

Therapeutic Potential of Leelamine, a Novel Inhibitor of Androgen Receptor and Castration-Resistant Prostate Cancer

Singh, K. B., Ji, X., & Singh, S. V. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0117 · Cited by 25

Androgen drives melanoma invasiveness and metastatic spread by inducing tumorigenic fucosylation

Liu, Q., Adhikari, E., Lester, D. K., Fang, B., Johnson, J., Tian, Y., Mockabee‐Macias, A., Izumi, V., Guzman, K. M., White, M. G., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-45324-w · Cited by 28

Selenite Treatment Inhibits LAPC-4 Tumor Growth and Prostate-Specific Antigen Secretion in a Xenograft Model of Human Prostate Cancer

Bhattacharyya, R. S., Husbeck, B., Feldman, D., & Knox, S. J. (2008) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2008.07.005 · Cited by 23

A reciprocal feedback between the PDZ binding kinase and androgen receptor drives prostate cancer

Warren, A. Y., Massie, C. E., Watt, K., Luko, K., Orafidiya, F. A., Selth, L. A., Mohammed, H., Chohan, B. S., Menon, S., Baridi, A., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0501-z · Cited by 23

Serum HER2 extracellular domain predicts an aggressive clinical outcome and biological PSA response in hormone-independent prostate cancer patients treated with docetaxel

Domenech, J. M. D., Fernández, P. L., Filella, X., Martinez-Fernandez, A., Molina, R., Fernández, E., Alcaraz, A., Codony, J., Gascón, P., & Mellado, B. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm490 · Cited by 24

Prognostic value of Her‐2/neu and DNA index for progression, metastasis and prostate cancer‐specific death in men with long‐term follow‐up after radical prostatectomy

Isharwal, S., Miller, M. C., Epstein, J. I., Mangold, L. A., Humphreys, E. B., Partin, A. W., & Veltri, R. W. (2008) · International Journal of Cancer · doi:10.1002/ijc.23838 · Cited by 24

Androgen Receptor Activation in Glioblastoma Can Be Achieved by Ligand-Independent Signaling through EGFR—A Potential Therapeutic Target

Zalcman, N., Gutreiman, M., Shahar, T., Weller, M., & Lavon, I. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222010954 · Cited by 23

The androgen receptor messenger RNA: what do we know?

Likos, E., Bhattarai, A., Weyman, C. M., & Shukla, G. C. (2022) · RNA Biology · doi:10.1080/15476286.2022.2084839 · Cited by 28

Longterm Followup Assessment of a HER2/ neu Peptide (E75) Vaccine for Prevention of Recurrence in High-Risk Prostate Cancer Patients

Gates, J. D., Carmichael, M. G., Benavides, L. C., Holmes, J. P., Hueman, M. T., Woll, M. M., Ioannides, C. G., Robson, C. H., McLeod, D. G., Ponniah, S., et al. (2009) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2008.10.018 · Cited by 23

A new era for castrate resistant prostate cancer: A treatment review and update

Fong, M. K., Hare, R. B., & Jarkowski, A. (2012) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155212437599 · Cited by 23

Inhibition of HER-2/neu Kinase Impairs Androgen Receptor Recruitment to the Androgen Responsive Enhancer

Liu, Y., Majumder, S., McCall, W., Sartor, C. I., Mohler, J. L., Gregory, C. W., Earp, H. S., & Whang, Y. E. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4292 · Cited by 99

Effect of type I growth factor receptor tyrosine kinase inhibitors on phosphorylation and transactivation activity of the androgen receptor in prostate cancer cells: Ligand-independent activation of the N-terminal domain of the androgen receptor

Sugita, S., Kawashima, H., Tanaka, T., Kurisu, T., Sugimura, K., & Nakatani, T. (2004) · Oncology Reports · doi:10.3892/or.11.6.1273 · Cited by 21

HER-2/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway.

Wen, Y., Hu, M. C. ‐., Makino, K., Spohn, B., Bartholomeusz, G. A., Yan, D., & Hung, M. (2000) · PubMed · Cited by 461

HER2/HER3 heterodimers in prostate cancer

Freeman, M. R. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.10.018 · Cited by 25

Androgen-Dependent Regulation of Her-2/neu in Prostate Cancer Cells

Berger, R., Lin, D. I., Nieto, M., Sicińska, E., Garraway, L. A., Adams, H., Signoretti, S., Hahn, W. C., & Loda, M. F. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3928 · Cited by 79